Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 4/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.32 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.32 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23601320 | 0.92 | MAT2A (0.35) | MAT2AHSD17B1HSD17B2CSNK2A2CSNK2B | |
| SCHEMBL31169405 | 0.90 | MAT2A (0.34) | MAT2AHSD17B1HSD17B2PRMT5 | |
| SCHEMBL23601049 | 0.90 | MAT2A (0.34) | MAT2AHSD17B1HSD17B2PRMT5 | |
| SCHEMBL23601437 | 0.89 | HSD17B1 (0.35) | MAT2AHSD17B1HSD17B2 | |
| SCHEMBL23601518 | 0.89 | MAT2A (0.33) | MAT2AHSD17B1HSD17B2 | |
| SCHEMBL23577347 | 0.88 | MAT2A (0.32) | MAT2AHSD17B1HSD17B2 | |
| SCHEMBL29909318 | 0.88 | MAT2A (0.32) | MAT2AHSD17B1HSD17B2DGAT1SOAT1 | |
| SCHEMBL23577071 | 0.88 | MAT2A (0.32) | MAT2AHSD17B1HSD17B2DGAT1SOAT1 | |
| SCHEMBL23578328 | 0.85 | MAT2A (0.35) | MAT2AMAPTHSD17B1HSD17B2CSNK2A2 | |
| SCHEMBL30961003 | 0.85 | MAPT (0.32) | MAPTHSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2022-10-13 | — | — | US | disclosed |
| WO-2021130638-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES, INC. (JP) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324866-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | MAT2A 1551/4885BRD4 539/4885MAPT 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.